| Send2Press.com • Today is Sunday, February 12, 2012 | A Member of the Neotrope News Network |  |
|
|
NEWS ARCHIVES : U.S. and World News :
Medical :
Drugs and Pharmaceuticals
News
|
Press Release:
Reaction Biology Receives NCI Grant Award for Epigenetic Platform
MALVERN, Pa., Aug. 11 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ("RBC") announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpotSM drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC's methyltransferase screens from 14 to 35 or more.RBC's HotSpot technology is an ultra-low volume tritium-based assay platform that provides gold-standard methyltransferase inhibition data. The technology is offered as a screening service, allowing clients to avoid operational issues related to dealing with radioisotope management, and quickly find productive lead candidates. RBC Chief Technology Officer Haiching Ma said, "Epigenetic mechanisms are increasingly recognized as fundamental to several cancers and many other diseases. Up until now, there has been no cost-effective way to do large-scale methyltransferase screening and profiling. We hope that RBC's ability to fill this unmet need will speed the discovery of new drugs in this area." Based in Malvern, PA, RBC specializes in providing high quality biochemical enzyme assay data, using ultra-low volumes and proprietary methods. RBC has provided its services to over 190 customers worldwide, including large pharmaceutical, biotech, government, and academic labs. RBC's Kinase HotSpotSM platform is a widely used service for providing high quality low-cost kinase screening data worldwide. The company also provides HDAC, protease, and other screening services, as well as custom assay development and partnerships. For more information, visit: www.reactionbiology.com.
NEWS SOURCE: Reaction Biology Corporation
Send2Press® is the originating wire service for this story. Terms of Use. © Reaction Biology Corporation. All trademarks acknowledged.
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE (Reaction Biology Corporation), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE.
Journalist Resources:
Download original press release as issued including media contact information for Reaction Biology Corporation.
Additional News Releases on Similar Topics:
|
Subscribe to Send2Press®
Daily News Releases by E-Mail
Follow Send2Press on Social Sites: 
Additional News from
Reaction Biology Corporation : » Reaction Biology Launches Recombinant Methyltransferase Line » Reaction Biology Receives NCI Grant Award for Epigenetic Platform » Key Organics Ltd and Reaction Biology Corporation Announce New Library Screening Format
|
||||||||||||||||||||||||||
View our news channels by industry topics, by U.S. States, or by selected U.S. Cities:
|
Terms of Use and License
This "article format" version of the issued press release is Copr. © 1983-2012 Neotrope/Send2Press. You may freely link to this article version of the press release or may use the release text as the basis for an original article or news posting. If the content is copied verbatim via a scraping or copy/paste method, the news item must be properly "attributed" to Send2Press® Newswire as the originating wire service for this story (may not be posted on ANY site selling/offering SEO or PR services, newswire services, or adult content!). |
DISCLAIMER: the above press release content is believed accurate but not guaranteed, and is based on business news supplied by the source. The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press (this website) makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope® or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
REFERENCES: Reaction Biology Receives NCI Grant Award for Epigenetic Platform, Reaction Biology Corporation, RBC Kinase HotSpot, HDAC, protease, and other screening services, epigenetic, methyltransferase, biotech, drug discovery, Haiching Ma, Phase II SBIR grant, National Cancer Institute, pharma, press release, Aug 11, 2010. |
|
THIS PAGE MEDIA READS (by media and public, as of today): 1990 times (3 today, 3 this week, 25 this month, 76 this year)
Site Design and Content is Copr. © 1983 - 2011 Neotrope® - All rights reserved. Send2Press® is a reg. trademark and service mark of NEOTROPE.
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)